Equity Overview
Price & Market Data
Price: $0.935
Daily Change: -$0.0101 / 1.08%
Daily Range: $0.935 - $0.978
Market Cap: $5,899,848
Daily Volume: 82,109
Performance Metrics
1 Week: -13.44%
1 Month: -26.96%
3 Months: -40.83%
6 Months: -49.19%
1 Year: -73.44%
YTD: -70.88%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.